Clinical observation of 10 cases of stable non-segmental vitiligo in adults treated with upadacitinib.

OBJECTIVE

To evaluate the efficacy and safety of upadacitinib in treating stable nonsegmental vitiligo in adults.

METHODS

Data were collected from adult patients with stable nonsegmental vitiligo treated with upadacitinib at Jingzhou Hospital of Yangtze University between November 2023 and November 2024. Treatment efficacy was compared at 8 and 16 weeks and any adverse reactions were recorded.

RESULTS

A total of 10 patients were included, 6 of whom also received 308 nm excimer laser therapy. A total of 200 lesions were observed, with 146 receiving additional laser therapy. After 8 weeks of treatment, 60.0% of lesions achieved at least 25% pigmentation, while 27.0% achieved more than 50% pigmentation. After 16 weeks, these rates increased to 78.0% and 52.5%, respectively. Treatment efficacy was greater at 16 weeks compared to 8 weeks ( < 0.001). Acral lesions showed lower response rates compared to lesions on the face, neck, trunk, and limbs ( < 0.05). There was no statistically significant difference in efficacy between upadacitinib monotherapy and combination therapy with phototherapy ( > 0.05). Among the 10 patients, 6 achieved over 50% improvement in total VASI score after 16 weeks, while 4 showed more than 75% improvement.

CONCLUSION

Upadacitinib is safe and effective treatment for stable non-segmental vitiligo in adults.